Reuters -- French drugmaker Sanofi-Aventis SA said on Friday U.S. regulators will review its BSI-201 experimental breast cancer drug on an accelerated basis and that a pivotal trial of the drug is on schedule.
Reuters -- French drugmaker Sanofi-Aventis SA said on Friday U.S. regulators will review its BSI-201 experimental breast cancer drug on an accelerated basis and that a pivotal trial of the drug is on schedule.
